416 related articles for article (PubMed ID: 31243370)
1. FOXA1 mutations alter pioneering activity, differentiation and prostate cancer phenotypes.
Adams EJ; Karthaus WR; Hoover E; Liu D; Gruet A; Zhang Z; Cho H; DiLoreto R; Chhangawala S; Liu Y; Watson PA; Davicioni E; Sboner A; Barbieri CE; Bose R; Leslie CS; Sawyers CL
Nature; 2019 Jul; 571(7765):408-412. PubMed ID: 31243370
[TBL] [Abstract][Full Text] [Related]
2. Distinct structural classes of activating FOXA1 alterations in advanced prostate cancer.
Parolia A; Cieslik M; Chu SC; Xiao L; Ouchi T; Zhang Y; Wang X; Vats P; Cao X; Pitchiaya S; Su F; Wang R; Feng FY; Wu YM; Lonigro RJ; Robinson DR; Chinnaiyan AM
Nature; 2019 Jul; 571(7765):413-418. PubMed ID: 31243372
[TBL] [Abstract][Full Text] [Related]
3. FOXA1 Mutations Reveal Distinct Chromatin Profiles and Influence Therapeutic Response in Breast Cancer.
Arruabarrena-Aristorena A; Maag JLV; Kittane S; Cai Y; Karthaus WR; Ladewig E; Park J; Kannan S; Ferrando L; Cocco E; Ho SY; Tan DS; Sallaku M; Wu F; Acevedo B; Selenica P; Ross DS; Witkin M; Sawyers CL; Reis-Filho JS; Verma CS; Jauch R; Koche R; Baselga J; Razavi P; Toska E; Scaltriti M
Cancer Cell; 2020 Oct; 38(4):534-550.e9. PubMed ID: 32888433
[TBL] [Abstract][Full Text] [Related]
4. Androgen receptor-independent function of FoxA1 in prostate cancer metastasis.
Jin HJ; Zhao JC; Ogden I; Bergan RC; Yu J
Cancer Res; 2013 Jun; 73(12):3725-36. PubMed ID: 23539448
[TBL] [Abstract][Full Text] [Related]
5. Chromatin binding of FOXA1 is promoted by LSD1-mediated demethylation in prostate cancer.
Gao S; Chen S; Han D; Wang Z; Li M; Han W; Besschetnova A; Liu M; Zhou F; Barrett D; Luong MP; Owiredu J; Liang Y; Ahmed M; Petricca J; Patalano S; Macoska JA; Corey E; Chen S; Balk SP; He HH; Cai C
Nat Genet; 2020 Oct; 52(10):1011-1017. PubMed ID: 32868907
[TBL] [Abstract][Full Text] [Related]
6. Pioneer of prostate cancer: past, present and the future of FOXA1.
Teng M; Zhou S; Cai C; Lupien M; He HH
Protein Cell; 2021 Jan; 12(1):29-38. PubMed ID: 32946061
[TBL] [Abstract][Full Text] [Related]
7. Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer.
Baca SC; Takeda DY; Seo JH; Hwang J; Ku SY; Arafeh R; Arnoff T; Agarwal S; Bell C; O'Connor E; Qiu X; Alaiwi SA; Corona RI; Fonseca MAS; Giambartolomei C; Cejas P; Lim K; He M; Sheahan A; Nassar A; Berchuck JE; Brown L; Nguyen HM; Coleman IM; Kaipainen A; De Sarkar N; Nelson PS; Morrissey C; Korthauer K; Pomerantz MM; Ellis L; Pasaniuc B; Lawrenson K; Kelly K; Zoubeidi A; Hahn WC; Beltran H; Long HW; Brown M; Corey E; Freedman ML
Nat Commun; 2021 Mar; 12(1):1979. PubMed ID: 33785741
[TBL] [Abstract][Full Text] [Related]
8. Heterarchy of transcription factors driving basal and luminal cell phenotypes in human urothelium.
Fishwick C; Higgins J; Percival-Alwyn L; Hustler A; Pearson J; Bastkowski S; Moxon S; Swarbreck D; Greenman CD; Southgate J
Cell Death Differ; 2017 May; 24(5):809-818. PubMed ID: 28282036
[TBL] [Abstract][Full Text] [Related]
9. FOXA1 inhibits prostate cancer neuroendocrine differentiation.
Kim J; Jin H; Zhao JC; Yang YA; Li Y; Yang X; Dong X; Yu J
Oncogene; 2017 Jul; 36(28):4072-4080. PubMed ID: 28319070
[TBL] [Abstract][Full Text] [Related]
10. LncRNA DSCAM-AS1 interacts with YBX1 to promote cancer progression by forming a positive feedback loop that activates FOXA1 transcription network.
Zhang Y; Huang YX; Wang DL; Yang B; Yan HY; Lin LH; Li Y; Chen J; Xie LM; Huang YS; Liao JY; Hu KS; He JH; Saw PE; Xu X; Yin D
Theranostics; 2020; 10(23):10823-10837. PubMed ID: 32929382
[No Abstract] [Full Text] [Related]
11. Noncoding mutations target cis-regulatory elements of the FOXA1 plexus in prostate cancer.
Zhou S; Hawley JR; Soares F; Grillo G; Teng M; Madani Tonekaboni SA; Hua JT; Kron KJ; Mazrooei P; Ahmed M; Arlidge C; Yun HY; Livingstone J; Huang V; Yamaguchi TN; Espiritu SMG; Zhu Y; Severson TM; Murison A; Cameron S; Zwart W; van der Kwast T; Pugh TJ; Fraser M; Boutros PC; Bristow RG; He HH; Lupien M
Nat Commun; 2020 Jan; 11(1):441. PubMed ID: 31974375
[TBL] [Abstract][Full Text] [Related]
12. Identification of lineage-specific epigenetic regulators FOXA1 and GRHL2 through chromatin accessibility profiling in breast cancer cell lines.
Yang L; Kumegawa K; Saeki S; Nakadai T; Maruyama R
Cancer Gene Ther; 2024 May; 31(5):736-745. PubMed ID: 38429368
[TBL] [Abstract][Full Text] [Related]
13. SPOP and FOXA1 mutations are associated with PSA recurrence in ERG wt tumors, and SPOP downregulation with ERG-rearranged prostate cancer.
Hernández-Llodrà S; Segalés L; Safont A; Juanpere N; Lorenzo M; Fumadó L; Rodríguez-Vida A; Cecchini L; Bellmunt J; Lloreta-Trull J
Prostate; 2019 Jul; 79(10):1156-1165. PubMed ID: 31090082
[TBL] [Abstract][Full Text] [Related]
14. Genome-wide characterisation of Foxa1 binding sites reveals several mechanisms for regulating neuronal differentiation in midbrain dopamine cells.
Metzakopian E; Bouhali K; Alvarez-Saavedra M; Whitsett JA; Picketts DJ; Ang SL
Development; 2015 Apr; 142(7):1315-24. PubMed ID: 25804738
[TBL] [Abstract][Full Text] [Related]
15. FOXA1 promotes prostate cancer angiogenesis by inducing multiple pro-angiogenic factors expression.
Su Y; Zhang Y; Zhao J; Zhou W; Wang W; Han B; Wang X
J Cancer Res Clin Oncol; 2021 Nov; 147(11):3225-3243. PubMed ID: 34258652
[TBL] [Abstract][Full Text] [Related]
16. Clinically-observed FOXA1 mutations upregulate SEMA3C through transcriptional derepression in prostate cancer.
Tam KJ; Liu L; Hsing M; Dalal K; Thaper D; McConeghy B; Yenki P; Bhasin S; Peacock JW; Wang Y; Cherkasov A; Rennie PS; Gleave ME; Ong CJ
Sci Rep; 2024 Mar; 14(1):7082. PubMed ID: 38528115
[TBL] [Abstract][Full Text] [Related]
17. Cooperativity and equilibrium with FOXA1 define the androgen receptor transcriptional program.
Jin HJ; Zhao JC; Wu L; Kim J; Yu J
Nat Commun; 2014 May; 5():3972. PubMed ID: 24875621
[TBL] [Abstract][Full Text] [Related]
18. Elevated levels of FOXA1 facilitate androgen receptor chromatin binding resulting in a CRPC-like phenotype.
Robinson JL; Hickey TE; Warren AY; Vowler SL; Carroll T; Lamb AD; Papoutsoglou N; Neal DE; Tilley WD; Carroll JS
Oncogene; 2014 Dec; 33(50):5666-74. PubMed ID: 24292680
[TBL] [Abstract][Full Text] [Related]
19. FOXA1 deletion in luminal epithelium causes prostatic hyperplasia and alteration of differentiated phenotype.
DeGraff DJ; Grabowska MM; Case TC; Yu X; Herrick MK; Hayward WJ; Strand DW; Cates JM; Hayward SW; Gao N; Walter MA; Buttyan R; Yi Y; Kaestner KH; Matusik RJ
Lab Invest; 2014 Jul; 94(7):726-39. PubMed ID: 24840332
[TBL] [Abstract][Full Text] [Related]
20. Dual role of FoxA1 in androgen receptor binding to chromatin, androgen signalling and prostate cancer.
Sahu B; Laakso M; Ovaska K; Mirtti T; Lundin J; Rannikko A; Sankila A; Turunen JP; Lundin M; Konsti J; Vesterinen T; Nordling S; Kallioniemi O; Hautaniemi S; Jänne OA
EMBO J; 2011 Sep; 30(19):3962-76. PubMed ID: 21915096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
